Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Spotlight Correspondence
  • Published:

Philadelphia-negative acute lymphoblastic leukemia developing in a CML patient in imatinib mesylate-induced complete cytogenetic remission

Leukemia volume 17, pages 2046–2048 (2003)Cite this article

TO THE EDITOR

Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell disorder characterized by the presence of a specific chromosome translocation t(9;22)(q34;q11).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM . The biology of chronic myeloid leukemia. N Engl J Med 1999; 341: 164–172.

    Article  CAS  Google Scholar 

  2. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645–652.

    Article  CAS  Google Scholar 

  3. Andersen MK, Pedersen-Bjergaard J, Kjeldsen L, Dufva IH, Brondum-Nielsen K . Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8. Leukemia 2002; 16: 1390–1393.

    Article  CAS  Google Scholar 

  4. Meeus P, Demuynck H, Martiat P, Michaux L, Wouters E, Hagemeijer A . Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with imatinib. Leukemia 2003; 17: 465–467.

    Article  CAS  Google Scholar 

  5. O'Dwyer ME, Gatter KM, Loriaux M, Druker BJ, Olson SB, Magenis RE et al. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia 2003; 17: 481–487.

    Article  CAS  Google Scholar 

  6. Livak KJ, Flood SJ, Marmaro J, Giusti W, Deetz K . Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Methods Appl 1995; 4: 357–362.

    Article  CAS  Google Scholar 

  7. Chee YL, Vickers MA, Stevenson D, Holyoake TL, Culligan DJ . Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones. Leukemia 2003; 17: 634–635.

    Article  CAS  Google Scholar 

  8. Ohtsuka E, Kikuchi H, Abe Y, Moriyama K, Ohno E, Hirota K et al. Acute myeloblastic leukaemia without Philadelphia chromosome developing after interferon therapy for chronic myelocytic leukaemia with Philadelphia chromosome. Br J Haematol 1995; 90: 951–953.

    Article  CAS  Google Scholar 

  9. Bose S, Chowdhry VP, Saxena R, Kucheria K . Lymphoid blast crisis during complete cytogenetic remission following interferon-alpha and hydroxyurea therapy. Acta Haematol 1997; 98: 155–159.

    Article  CAS  Google Scholar 

  10. Dawson L, Slater R, Hagemeijer A, Langerak AW, Willemze R, Kluin-Nelemans JC . Secondary T-acute lymphoblastic leukaemia mimicking blast crisis in chronic myeloid leukaemia. Br J Haematol 1999; 106: 104–106.

    Article  CAS  Google Scholar 

  11. Manley R, Cochrane J, McDonald M, Rigby S, Moore A, Kirk A et al. Clonally unrelated BCR-ABL-negative acute myeloblastic leukemia masquerading as blast crisis after busulphan and interferon therapy for BCR-ABL-positive chronic myeloid leukemia. Leukemia 1999; 13: 126–129.

    Article  CAS  Google Scholar 

  12. Flamm MJ, Murty VV, Rao PH, Nichols GL . Coexistence of independent myelodysplastic and Philadelphia chromosome positive clones in a patient treated with hydroxyurea. Leuk Res 2002; 26: 417–420.

    Article  Google Scholar 

Download references

Acknowledgements

This text presents research results of the Belgian programme on Interuniversity Poles of Attraction initiated by the Belgian State, Prime Minister's Office, Science Policy Programming. The scientific responsibility is assumed by the authors.

Author information

Authors and Affiliations

  1. Hematology Unit, Hôpital de Jolimont, Haine-Saint-Paul, Belgium

    S Cherrier-De Wilde & A Delannoy

  2. Institute of Pathology and Genetics, Loverval, Belgium

    K Rack & P Vannuffel

  3. Department of Human Genetics, University of Leuven, Leuven, Belgium

    A Hagemeijer

Authors
  1. S Cherrier-De Wilde
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Rack
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P Vannuffel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Delannoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Hagemeijer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wilde, SD., Rack, K., Vannuffel, P. et al. Philadelphia-negative acute lymphoblastic leukemia developing in a CML patient in imatinib mesylate-induced complete cytogenetic remission. Leukemia 17, 2046–2048 (2003). https://doi.org/10.1038/sj.leu.2403094

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403094

This article is cited by

Search

Advanced search

Quick links